Project Grant K08HL183778
Award Date 8/15/26
Completion Date 7/31/31
Dollars Obligated $169K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $170,432 under Project Grant K08HL183784 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). Dr. Urbut will develop and validate a novel Bayesian multivariate model integrating time-varying genetic and clinical factors across over 300 diagnostic phenotypes to identify latent disease signatures for genomic discovery and produce...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the Massachusetts General Hospital's Research Management Division $842,536 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms linking gestational diabetes mellitus (GDM) to increased coronary artery disease risk in women. The research integrates longitudinal electronic health records data spanning approximately 30 years postpartum for more than 208,000 women with GDM...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 1, 2026, for whole genome sequence interpretation to identify new genes and mechanisms underlying coronary artery disease and familial hypercholesterolemia. The award funds research to improve genetic diagnostic yield for familial hypercholesterolemia, an inherited form of...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $391,700 under the Cardiovascular Diseases Research program (CFDA 93.837) on February 15, 2026. The award funds mixed-methods health services research to optimize the regionalization of care for acute type A aortic dissection (ATAAD) and increase appropriate interfacility transfer of ATAAD patients from low-volume to high-volume aortic centers. The research...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,401,048 for Project Grant R01HL184086 on September 1, 2026 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds GO MOMS PREDICT, a prospective study that develops and tests pregnancy-based cardiovascular disease risk assessment models to predict cardiovascular outcomes five years after delivery. The study leverages an existing...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $330,176 on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mentored research on the effect of severe obesity on regional lung perfusion in acute hypoxemic respiratory failure. The award funds two primary research aims. Aim 1 defines the association between severe obesity and regional lung perfusion in a novel...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $867,656 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to develop and apply comparative effectiveness evidence methods for evaluating medical therapies in heart failure with mildly reduced ejection fraction (HFMREF). The award funds completion of the largest echocardiography registry in the world and application of regression discontinuity...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $802,156 under Project Grant R01HL183169 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of diffusion tensor magnetic resonance imaging (DTI) techniques to image the microstructure of the human right ventricle in vivo. The recipient will develop a diffusion-encoded MRI sequence compensated for...